Moderna’s experimental mRNA cancer treatment progresses, shares spike

Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine designed to be tailored to individual patients based on unique mutations within their tumors.

Moderna Shares More Than Double on Success of mRNA Cancer Vaccine  WSJ

Pharmaceutical companies Moderna and Merck announced today the highly promising results of their anti-cancer mRNA vaccine Phase 3 clinical trial targeting later-stage melanoma skin cancers. Researchers sequenced the DNA from each patient's tumors to create personalized vaccines that, when injected, rev up the immune sy

The biopharmaceutical sector has struggled with a prolonged downturn in recent years but has been on an upswing of late.

US stocks are ticking higher after the US Treasury Department said it will buy more US government bonds in a move that eased pressure on financial markets worldwide.

US stocks are ticking higher after the US Treasury Department said it will buy more US government bonds in a move that eased pressure on financial markets worldwide.

Moderna shares jump 150% on skin cancer trial success  The Times

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

The results mark a step forward in the effort to treat not just melanoma but other forms of cancer with vaccines designed to help keep patients disease-free.

Drugmaker’s melanoma shot developed with Merck delivers positive outcome in late-stage trial

The vaccine reportedly thwarted the cancer's return and spread.

Moderna shares double as cancer vaccine data rekindles investor hopes  Reuters

Pharmaceutical giants Moderna and Merck said that an experimental vaccine treatment has shown signs of preventing cancer from returning or spreading in a study of high-risk melanoma patients. NBC News health reporter Aria Bendix explains what happens next.

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test  AP News

Moderna shares more than doubled after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind.

Moderna Shares Skyrocket 125% Toward Best Day Ever—Here’s Why  Forbes

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.

A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage testing results.

Moderna stock surged after its mRNA cancer vaccine showed positive Phase 3 results with Merck’s Keytruda, boosting hopes for a new melanoma treatment.

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.   The positive results mean a potentially life-extending treatment is one step closer to being a

Stock prices for the American vaccine manufacturer Moderna more than doubled on Wednesday after the company reported successful results from its messenger RNA melanoma cancer vaccine.  The mRNA shot, in combination with Merck’s immunotherapy drug Keytruda, met critical benchmarks in a global late-stage clinical trial o

Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck’s immunotherapy medication Keytruda, met initial goals in a late-stage trial.  The ongoing mRNA cancer vaccine study involves 1,137 patients with high-risk melanoma that has been surgically removed. In early results

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

President Trump is expected to nominate Heidi Overton, White House deputy director of domestic policy, to serve as the next FDA commissioner

An mRNA success is something of a vindication for Trump (and the Biden years), but an embarrassment for RFK Jr.

Optimism about a potential breakthrough in personalised cancer treatment has sent shares in Moderna soaring by nearly 100%.

The mRNA-based vaccine combined with Keytruda reduced melanoma recurrence in more than 1,100 patients whose cancer had been surgically removed

Women with breast cancer who were left languishing in PBS drug uncertainty have been offered a lifeline.

A JAMA Surgery study of over two million patients found that cancer treatment delays grew by more than 10 days across six disease types.